News - Valeant Pharmaceuticals, Bausch & Lomb

Filter

Popular Filters

1 to 25 of 59 results

Valeant Pharma returns to profit, boosted by B&L acquisition

27-02-2014

Canadian drugmaker Valeant Pharmaceuticals International has announces fourth quarter financial results…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio

03-02-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Patent settlements for Pfizer/Teva and Mylan/Eisai

Patent settlements for Pfizer/Teva and Mylan/Eisai

18-12-2013

US pharma behemoth Pfizer says it has settled its long-standing litigation against a US subsidiary of…

Banner PharmacapsEisaiGenericsLegalMen's HealthMylan LaboratoriesNorth AmericaOncologyPatentsPfizerTargretinTeva Pharmaceutical IndustriesValeant PharmaceuticalsViagra

Valeant agrees $142.5 million settlement with Anacor

28-10-2013

Anacor Pharmaceuticals says it has entered into a $142,5 million settlement agreement with Canada-based…

Anacor PharmaceuticalsFinancialLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Anacor Pharma awarded $100 million damages

18-10-2013

Anacor Pharmaceuticals says that the arbitrator appointed to resolve its dispute with Canada-based Valeant…

Anacor PharmaceuticalsLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Valeant Pharma beats forecasts, turns in profit

07-08-2013

Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) announced second quarter financial…

Bausch & LombFinancialGenericsValeant Pharmaceuticals

Bausch & Lomb options license to DES compound

18-07-2013

US eye health giant Bausch & Lomb (NYSE: BOL) says it has acquired an option to license an investigational…

Bausch & LombLicensingMIM-D3Mimetogen PharmaceuticalsOphthalmicsPharmaceutical

Valeant confirms plan to acquire Bausch & Lomb in a $8.7 billion transaction

28-05-2013

Following speculation ahead of the extended holiday weekend, acquisitive Canadian drugmaker Valeant Pharmaceuticals…

Bausch & LombMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

ISTA Pharma pleads guilty to federal felony charges in $33.5 million settlement; parent Bausch & Lomb a Valeant takeover target?

27-05-2013

US drugmaker ISTA Pharmaceuticals has pleaded guilty to conspiracy to introduce a misbranded drug into…

Bausch & LombISTA PharmaceuticalLegalMarkets & MarketingMergers & AcquisitionsNorth AmericaPharmaceuticalValeant PharmaceuticalsXibrom

Actavis and Valeant report first quarter 2013 results

02-05-2013

US generics drug major Actavis (NYSE: ACT) and Canada's Valeant Pharmaceuticals (TSX: VRX) both presented…

ActavisFinancialGenericsValeant Pharmaceuticals

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?

29-04-2013

US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Actavis settles with Valeant to launch generic Ziana and Zyclara in USA

11-04-2013

US generics drug major Actavis (NYSE: ACT) has reached settlement agreements with Medicis Pharmaceutical,…

ActavisGenericsMarkets & MarketingNorth AmericaPatentsValeant PharmaceuticalsZiana GelZyclara

Actavis and Valeant to co-promote Zovirax and Cordran Tape

07-04-2013

Valeant Pharmaceuticals International (TSX: VRX) entered into an agreement, effective immediately, for…

ActavisAnti-viralsCordran TapeGenericsLicensingMarkets & MarketingMylan LaboratoriesNorth AmericaValeant PharmaceuticalsZovirax Ointment

Merz Pharma enters bidding war for Obagi; Ferro sells pharma unit

02-04-2013

German family-owned firm Merz Pharma has written to the board of director of Obagi Medical Products outlining…

Ferro GroupGenericsMergers & AcquisitionsMerz PharmaceuticalsObagi Medical ProductsPfanstiehl LaboratoriesPharmaceuticalValeant Pharmaceuticals

Valeant to acquire Obagi Medical for around $344 million

20-03-2013

Canada-based Valeant Pharmaceuticals International (TSX: VRX) is on the acquisition trail again, announcing…

DermatologicalsMergers & AcquisitionsObagi Medical ProductsPharmaceuticalValeant Pharmaceuticals

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

Bausch & Lomb said to be on the block for $10 billion

13-12-2012

A Bloomberg report says that Warburg Pincus, which acquired the business in 2007, has appointed Goldman…

Bausch & LombMergers & AcquisitionsOphthalmicsPharmaceutical

News briefs from Bayer, AstraZeneca and Valeant/Galderma

06-12-2012

German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

Valeant may pull out of Russian Natur Produkt acquisition

02-10-2012

According to local sources in Russia, acquisitive Canadian drugmaker Valeant Pharmaceuticals (TSX: VRX)…

Mergers & AcquisitionsNatur ProduktPharmaceuticalValeant Pharmaceuticals

1 to 25 of 59 results

Back to top